期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | IMMUNOLOGICAL INVESTIGATIONS LetPub Score 6.1
50 ratings
Rate
Reputation 7.4 Influence 4.9 Speed 7.0 | ||||||||||||||||
期刊簡稱 | IMMUNOL INVEST | ||||||||||||||||
ISSN | 0882-0139 | ||||||||||||||||
E-ISSN | 1532-4311 | ||||||||||||||||
h-index | 42 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://www.tandfonline.com/toc/iimm20/current | ||||||||||||||||
在線稿件提交 | https://mc.manuscriptcentral.com/limm | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Informa Healthcare | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||
創刊年 | 0 | ||||||||||||||||
每年文章數 | 60每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 6.53% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0882-0139%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[IMMUNOLOGICAL INVESTIGATIONS] 的評論 | 撰寫評論 |
作者: 寂灭慕梅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-08-28 18:38:09 評論於 Review Speed: 1.0 | Submission Hit Rate: 95.0 Research focus: Autoimmune diseases; Inflammation Experience sharing: Submitted on March 22, 2024 With Editor on March 24, 2024 Out for Review on April 24, 2024 Revision Required on July 10, 2024 Revision Incomplete on July 10, 2024 Revised Manuscript Submitted on July 15, 2024 With Editor on July 15, 2024 Out for Review on August 11, 2024 Accepted: The acceptance and publication process took about half a month and was very detailed. It is relatively easy to get published, suitable for graduation articles.(0) 讚! | 寂灭慕梅 |
作者: 寂灭慕梅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-08-14 19:46:58 評論於 His APC is very expensive, it's already 26,000 yuan.(0) 讚! | 寂灭慕梅 |
作者: 寂灭慕梅 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-08-12 19:51:49 評論於 Manual input, then there will be options to choose from.(0) 讚! | 寂灭慕梅 |
作者: 岳家婉清 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-06-22 16:47:05 評論於 Why can't departments and organizations make choices?(0) 讚! | 岳家婉清 |
作者: 龙鳞奕洳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-04-18 23:01:02 評論於 Review speed: 3.0 | Submission hit rate: 75.0 Emphasized research direction: Immunology; Osteoarthritis Experience sharing: The editorial process took one week to be sent for review, and the revisions were completed in two weeks by external reviewers. Acceptance was granted after nearly four months of the second review(0) 讚! | 龙鳞奕洳 |
作者: 雨巷少年怿悦 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-26 19:24:41 評論於 How long did it take you to finish?(0) 讚! | 雨巷少年怿悦 |
作者: 树行小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-05 17:39:19 評論於 Has your article been published? How long does it take from submission to acceptance?(0) 讚! | 树行小姐姐 |
作者: 京城统勋 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-01-11 19:19:35 評論於 How long does it usually take from receiving the proof to the final design?(0) 讚! | 京城统勋 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 22:48:12 評論於 Manuscript of the article(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 10:27:30 評論於 Currently ORCID is optional, not mandatory. However, it is important to note that most publishers (including Elsevier, Wiley, Nature, Thomsen Reuters) now require all researches related to their publications to use an ORCID iD. 19. How to add an ORCID ID if the article has been published without it? ORCID stands for Open Researcher and Contributor ID. ORCID iD is a unique and persistent academic identity for contributors, allowing authors to be distinguished from other researchers and keeping a record of all their related research activities. To add an ORCID iD for an article that has already been published, you will need to log in to the account of each author and associate the ORCID iD in the account information settings(0) 讚! | 维尔娜菲茨杰拉德 |
作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 11:25:38 評論於 Is it necessary to provide the ORCID ID of each author when submitting a manuscript?(0) 讚! | Darlene Pepys |
作者: 平原文波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 20:37:06 評論於 What is MS?(0) 讚! | 平原文波 |
作者: 猫巷少女逸思 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-03-27 09:33:25 評論於 Just submitted my application, hoping to be accepted(0) 讚! | 猫巷少女逸思 |
作者: 平原映云 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-07-06 13:55:51 評論於 How long does it generally take from acceptance to publication?(0) 讚! | 平原映云 |
作者: alsahebfosoul@med.mui.ac.ir 領域: 医药科学 審稿時間: 6.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-08-03 09:04:39 評論於 Effect of Fingolimod on the frequency of regulatory T cells in patients with relapsing-remitting multiple sclerosis. ID is LIMM-2018-0117.(0) 讚! | alsahebfosoul@med.mui.ac.ir |
作者: alsahebfosoul@med.mui.ac.ir 領域: 医药科学 審稿時間: 6.0 month(s) 結果: 修改後接受 撰寫評論 |
2018-08-03 09:04:26 評論於 Effect of Fingolimod on the frequency of regulatory T cells in patients with relapsing-remitting multiple sclerosis.ID is LIMM-2018-0117. (0) 讚! | alsahebfosoul@med.mui.ac.ir |
作者: 桃花觅风 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-05-28 18:41:35 評論於 Around one month Huihui 2016-05-28 Posted: SCI(2014):1.991 Why hasn't anyone written about their experiences? How long does the first review take?(0) 讚! | 桃花觅风 |
作者: 子童姑娘 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-05-28 15:19:40 評論於 Why is nobody writing their experiences? How long does the first review take?(0) 讚! | 子童姑娘 |
作者: Theresa Edward 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2015-11-09 19:57:29 評論於 Review Speed: 3.0 | Submission Success Rate: 50.0 Experience Share: Submitted online for half a year(0) 讚! | Theresa Edward |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us